Glaucoma Surgical Devices Market By Type (Glaucoma Drainage Devices, Micro-Invasive Glaucoma Surgery (MIGS) Devices, Laser Devices), By Surgical Technique (Ab-Externo Surgery, Ab-Interno Surgery), By End-Use Industry (Hospitals, Ambulatory Surgical Centers, Ophthalmic Clinics), By Patient Type (Adult Patients, Pediatric Patients), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Glaucoma Surgical Devices Market was valued at USD 2.5 billion in 2023 and will surpass USD 5.0 billion by 2030; growing at a CAGR of 10.4% during 2024 - 2030.

The glaucoma surgical devices market has been expanding rapidly as glaucoma continues to be one of the leading causes of irreversible blindness worldwide. According to the World Health Organization (WHO), the global prevalence of glaucoma is on the rise, particularly among the aging population. This has led to a heightened demand for effective surgical treatments and cutting-edge devices. As the incidence of glaucoma increases across various demographics, including younger individuals, the need for improved glaucoma management and surgical solutions has become more pressing.

Advancements in technology have revolutionized glaucoma surgery, with an increasing emphasis on minimally invasive techniques that reduce recovery time and surgical risks. Traditional glaucoma surgeries, such as trabeculectomy, are being supplemented or replaced by newer technologies like micro-invasive glaucoma surgery (MIGS). These techniques, often involving smaller incisions and faster healing times, have improved patient outcomes significantly. Furthermore, the availability of more advanced diagnostic tools and surgical devices has made it easier for ophthalmologists to treat glaucoma effectively and with fewer complications. This growth in device innovation and the shift towards minimally invasive techniques are driving the market forward.

MIGS Devices Are Fastest Growing Owing to Rising Preference for Minimally Invasive Options

Micro-Invasive Glaucoma Surgery (MIGS) devices have emerged as the fastest-growing segment in the glaucoma surgical devices market. MIGS procedures are designed to treat glaucoma through small, minimally invasive incisions, using devices that improve intraocular pressure (IOP) control with less tissue damage and quicker recovery times than traditional surgeries. These devices have gained popularity because they provide effective IOP reduction while minimizing the risk of complications such as infection, scarring, or extended recovery periods. As the global preference shifts towards surgeries that are not only effective but also carry lower risks and shorter recovery times, MIGS is becoming the go-to choice for many patients and healthcare professionals.

One of the key factors driving the growth of the MIGS segment is its efficacy in managing glaucoma, particularly in early to moderate stages. MIGS procedures are often preferred by patients who are looking for a less invasive treatment option than traditional glaucoma surgeries. The reduced need for long hospital stays and fewer follow-up appointments further contribute to its increasing popularity. In addition, the availability of a variety of MIGS devices that cater to different types of glaucoma and patient needs is expanding the market. With continuous advancements in MIGS technology, including more durable devices and greater precision in IOP control, the MIGS segment is expected to maintain its strong growth trajectory in the coming years.

Ab-Interno Surgery Is Largest Surgical Technique Due to Enhanced Safety and Outcomes

The ab-interno surgical technique remains the dominant surgical approach in the glaucoma surgical devices market. This technique, which involves accessing the eye's drainage system through the inner eye layers, has garnered widespread adoption due to its safety, precision, and minimal invasiveness. Unlike traditional ab-externo procedures that require external incisions, ab-interno surgery offers reduced risks of complications and shorter recovery periods for patients. Surgeons have embraced this technique because of its ability to provide long-term intraocular pressure (IOP) reduction, a critical factor in the successful management of glaucoma.

The integration of advanced MIGS devices into the ab-interno procedure has further enhanced its popularity. Many MIGS devices, including stents and implants, are specifically designed for ab-interno surgeries, enabling better outcomes. The combination of these devices with the ab-interno technique provides a safer and more efficient way of managing glaucoma, especially in patients with moderate or advanced disease. The increasing number of clinical trials and studies supporting the efficacy of ab-interno surgery is also contributing to its growing prominence in the glaucoma treatment landscape. As a result, ab-interno surgery remains the largest segment, catering to a wide range of patients and ensuring long-term glaucoma management success.

Hospitals Lead End-Use Industry Owing to Advanced Infrastructure

Hospitals represent the largest end-use segment for glaucoma surgical devices. Their dominance is primarily attributed to their advanced infrastructure, specialized ophthalmic departments, and the availability of skilled medical professionals who can handle complex procedures. Hospitals are often equipped with the latest technologies and devices, which makes them the preferred setting for glaucoma surgeries. Furthermore, hospitals provide the necessary post-operative care and follow-up treatment, which is essential for glaucoma patients who require long-term monitoring.

The increasing demand for surgical treatments for glaucoma is fueling the growth of hospitals as a key player in the market. Many hospitals have dedicated glaucoma centers or departments with cutting-edge diagnostic tools and surgical instruments that allow for precise treatment. As glaucoma cases continue to rise globally, particularly among older adults, hospitals are expected to see sustained growth in the number of surgical procedures performed. The continued development of specialized centers within hospitals, along with advances in surgical techniques, will ensure that hospitals remain at the forefront of glaucoma care.

Adult Patients Drive Market Growth Due to High Glaucoma Prevalence

Adult patients constitute the largest patient demographic in the glaucoma surgical devices market. The high prevalence of glaucoma in older populations, coupled with the increasing risk factors associated with aging, has made adults the primary group requiring surgical intervention. As people live longer and the global population ages, the incidence of glaucoma increases, further driving the demand for surgical treatments. Glaucoma is often diagnosed in adults during routine eye exams, and once detected, surgical options are frequently recommended to manage intraocular pressure (IOP) and prevent vision loss.

The rise in adult patient numbers has also been influenced by growing awareness of the disease and its symptoms. With more individuals seeking early intervention, the adoption of surgical treatments has accelerated. Additionally, the availability of less invasive surgical options, such as MIGS, has made glaucoma surgery more accessible and appealing to adult patients, especially those in the early stages of the disease. As a result, adult patients remain the driving force behind the growth of the glaucoma surgical devices market.

North America Dominates Market Due to Advanced Healthcare Infrastructure

North America holds the largest share of the glaucoma surgical devices market, driven by a well-established healthcare infrastructure, high rates of glaucoma diagnosis, and early adoption of innovative surgical technologies. The U.S., in particular, is a global leader in the research, development, and commercialization of advanced glaucoma surgical devices. The country's robust healthcare system, combined with significant government investments in healthcare innovation and research, has positioned North America as the dominant region in the market.

Furthermore, North America benefits from an aging population, with a higher prevalence of glaucoma in older individuals. The growing awareness of glaucoma symptoms and the need for early treatment have contributed to the region's market growth. The high standard of care in North America, coupled with the availability of advanced surgical procedures and effective treatment options, continues to drive the demand for glaucoma surgical devices. As a result, North America is expected to maintain its leadership position in the market, with ongoing innovation and patient-centric care ensuring sustained growth.

Competitive Landscape: A Focus on Innovation

The glaucoma surgical devices market is highly competitive, with several key players driving innovation and competing for market share. Companies such as Alcon, Glaukos Corporation, and Ivantis, Inc. are leading the charge by investing heavily in research and development to introduce new, more effective devices. These companies focus on enhancing the efficacy of their products while ensuring greater safety and improved outcomes for patients. With the rise of minimally invasive surgeries, the competition has intensified as firms vie to develop devices that offer quicker recovery times and superior results.

Moreover, companies are adopting strategies such as mergers and acquisitions, partnerships, and product diversification to strengthen their market position. The increasing number of clinical studies validating the effectiveness of new surgical devices also plays a crucial role in fostering competition and spurring further innovation. As the market evolves, companies will continue to focus on developing cutting-edge solutions that meet the growing demand for safer, more effective glaucoma treatments, ensuring that the competitive landscape remains dynamic and forward-looking.

Recent Developments:

• In November 2024, Alcon Inc. launched an advanced MIGS implant targeting early-stage glaucoma patients, enhancing its product portfolio.
• In October 2024, Glaukos Corporation introduced an upgraded iStent system with improved efficacy for long-term intraocular pressure control.
• In September 2024, Johnson & Johnson Vision acquired a leading glaucoma drainage device manufacturer to expand its surgical product offerings.
• In August 2024, Sight Sciences, Inc. announced FDA approval for its new ab-interno glaucoma surgical device, designed for better patient outcomes.
• In July 2024, Lumenis Ltd. unveiled a next-generation laser system for selective laser trabeculoplasty (SLT), featuring enhanced precision and safety.

List of Leading Companies:

• In November 2024, Alcon Inc. launched an advanced MIGS implant targeting early-stage glaucoma patients, enhancing its product portfolio.
• In October 2024, Glaukos Corporation introduced an upgraded iStent system with improved efficacy for long-term intraocular pressure control.
• In September 2024, Johnson & Johnson Vision acquired a leading glaucoma drainage device manufacturer to expand its surgical product offerings.
• In August 2024, Sight Sciences, Inc. announced FDA approval for its new ab-interno glaucoma surgical device, designed for better patient outcomes.
• In July 2024, Lumenis Ltd. unveiled a next-generation laser system for selective laser trabeculoplasty (SLT), featuring enhanced precision and safety.

Report Scope: